Drug name - Promacta Kit

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7160870 NOVARTIS Thrombopoietin mimetics
Nov, 2022

(a month from now)

US7547719 NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Jul, 2025

(2 years from now)

CN101343250A NOVARTIS Thrombopoietin Mimics
May, 2020

(2 years ago)

CN101343251B NOVARTIS Thrombopoietin Mimetics
May, 2020

(2 years ago)

CN101343250B NOVARTIS Thrombopoietin Mimetics
May, 2020

(2 years ago)

CN101343251A NOVARTIS Thrombopoietin Mimetics
May, 2020

(2 years ago)

CN100423721C NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

CN1444477A NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

CN100542530C NOVARTIS 3 '-[(2Z)-[3 - (1, 4-Dimethylphenyl) 1, 5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4] Hydrazino] 2 ' - Hydroxy - [1 1 ' - Biphenyl] - 3-Di - (Monoethanolamine)
May, 2023

(7 months from now)

CN1652842A NOVARTIS 3 '-[(2Z)-[3 - (1, 4-Dimethyl-Phenyl)--1, 5-Dihydro - -3 - Methyl - -5 - Oxo - -4H - Pyrazol - -4 - Pyrazol-4-Ylidene] Hydrazino] -2 ' - Hydroxy - [1 1 ' - Biphenyl]--3 - Di - (Monoethanolamine)
May, 2023

(7 months from now)

IN200201666P3 NOVARTIS A Compound And A Pharmaceutical Composition For Use In Enhancing Platelet Production
May, 2021

(1 year, 4 months ago)

IN213176B NOVARTIS A Compound And A Pharmaceutical Composition For Use In Enhancing Platelet Production
May, 2021

(1 year, 4 months ago)

IN200403400P1 NOVARTIS 3'-[(2Z)-[1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene]Hydrazino]-2'-Hydroxy-[1,2'-Biphenyl]-3-Carboxylic Acid Bis-(Monoethanolamine)
May, 2023

(7 months from now)

IN233161B NOVARTIS 3'-[(2Z)-[1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene]Hydrazino]-2'-Hydroxy-[1,1'-Biphenyl]-3-Carboxylic Acid Bis-(Monoethanolamine)
May, 2023

(7 months from now)

EP1889838B1 NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

EP1889838A1 NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

EP1864981A1 NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

EP1864981B1 NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

EP1864981B8 NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

EP1534390B1 NOVARTIS 3'- (2Z)- 1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene Hydrazino -2'-Hydroxy- 1,1'-Biphenyl -3-Carboxylic Acid Bis-(Monoethanolamine)
May, 2023

(7 months from now)

EP1534390A2 NOVARTIS 3'- (2Z)- 1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene Hydrazino -2'-Hydroxy- 1,1'-Biphenyl -3-Carboxylic Acid Bis-(Monoethanolamine)
May, 2023

(7 months from now)

EP1534390A4 NOVARTIS 3'- (2Z)- 1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene Hydrazino -2'-Hydroxy- 1,1'-Biphenyl -3-Carboxylic Acid Bis-(Monoethanolamine)
May, 2023

(7 months from now)

EP1294378A2 NOVARTIS Thrombopoietin Mimetics
Mar, 2025

(2 years from now)

EP1294378B1 NOVARTIS Thrombopoietin Mimetics
Mar, 2025

(2 years from now)

EP1294378A4 NOVARTIS Thrombopoietin Mimetics
Mar, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7160870

(Pediatric)

NOVARTIS Thrombopoietin mimetics May, 2023

(7 months from now)

US7795293 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) May, 2023

(7 months from now)

US7795293

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Nov, 2023

(1 year, 1 month from now)

US7547719

(Pediatric)

NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) Jan, 2026

(3 years from now)

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Treatment: Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG ACID/PACKET FOR SUSPENSION;ORAL Prescription
EQ 25MG ACID/PACKET FOR SUSPENSION;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.